Literature DB >> 9790450

Effectiveness of leukocyte interferon-alpha treatment in patients with chronic hepatitis C not responsive to recombinant interferon.

G Scotto1, M Grimaldi.   

Abstract

Twenty-four patients with chronic active HCV infection, nonresponders to a previous treatment cycle with recombinant interferon-alpha (r-IFNA), underwent retreatment with leukocyte (LE-) IFN-alpha. This was administered at the dose of 3 MU three times a week, for either six months (group A) or 12 months (group B). All patients were followed-up for a further 12 months. ALT levels significantly (P < 0.05) decreased in group A, with complete response in three cases and a partial response in a further three at the end of treatment. During follow-up all patients again showed increases in ALT values. In group B also ALT significantly (P < 0.05) decreased, with two complete and five partial responses. During follow-up, apart from two patients with partial responses who relapsed, all maintained their initial response. At the end of treatment HCV RNA was no longer detectable in complete responders of both groups, while it was found reduced in those partial responders who maintained their response during follow-up. Partially responding subjects treated for six months evidenced higher levels than those treated for 12 months. IFN-alpha retreatment could therefore be effective in previously nonresponding patients, with a change in the type of interferon administered and the use of higher dosages and/or longer treatment periods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790450     DOI: 10.1023/a:1026693901012

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.

Authors:  R Schvarcz; H Glaumann; O Weiland; G Norkrans; R Wejstål; A Frydén
Journal:  Scand J Infect Dis       Date:  1991

2.  Changes in interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon.

Authors:  S Nakajima; T Kuroki; M Shintani; O Kurai; T Takeda; S Nishiguchi; S Shiomi; S Seki; K Kobayashi
Journal:  Hepatology       Date:  1990-12       Impact factor: 17.425

3.  Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions.

Authors:  C J Oon
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection.

Authors:  M Milella; G Antonelli; T Santantonio; M Currenti; L Monno; N Mariano; G Angarano; F Dianzani; G Pastore
Journal:  Liver       Date:  1993-06

5.  Short and long-term effects of interferon on serum markers of hepatitis C virus replication.

Authors:  H Yatsuhashi; O Inoue; K Inokuchi; M Koga; S Nagataki; T A Cha; B Irvine; M Stempien; J Kolberg; M S Urdea
Journal:  J Gastroenterol Hepatol       Date:  1993 Jan-Feb       Impact factor: 4.029

6.  Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.

Authors:  M R Jacyna; M G Brooks; R H Loke; J Main; I M Murray-Lyon; H C Thomas
Journal:  BMJ       Date:  1989-01-14

7.  Human leucocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alfa 2a.

Authors:  M Merup; E Törnebohm-Roche; K Engman; C Paul
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

8.  Lymphoblastoid alpha-interferon for chronic hepatitis C: a randomized controlled study.

Authors:  A Castilla; J Camps-Bansell; M P Civeira; J Prieto
Journal:  Am J Gastroenterol       Date:  1993-02       Impact factor: 10.864

9.  A pilot study of ribavirin therapy for chronic hepatitis C.

Authors:  A M Di Bisceglie; M Shindo; T L Fong; M W Fried; M G Swain; N V Bergasa; C A Axiotis; J G Waggoner; Y Park; J H Hoofnagle
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

10.  Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.

Authors:  G Antonelli; M Currenti; O Turriziani; F Dianzani
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

View more
  1 in total

1.  Human leukocyte interferon-alpha treatment for chronic HCV-related hepatitis in hemophilic patients previously intolerant to other interferons-alpha.

Authors:  Luca Dughera; Edda Battaglia; Anna Maria Serra; Daniela Tibaudi; Giuseppina Buonafede; Monica Navino; Piercarla Schinco; Giacomo Tamponi; Giorgio Emanuelli
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.